Title of article :
Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
Author/Authors :
Tajvidi ، Mina نويسنده Department of Radiation Oncology, Isfahan University of
Medical Sciences, Isfahan, Iran , , Roayaei ، Mahnaz نويسنده Department of Radiation Oncology , , Hematti، Simin نويسنده Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran , , Faezi، Hadi نويسنده Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran ,
Abstract :
Background: Metastatic prostate cancer is one of the most important cancers
among men worldwide. Androgen ablation therapy can be used in treatment of these
patients; however, most will progress to metastatic hormone-refractory prostate cancer.
In this regard, docetaxel has been approved to treat metastatic hormone-refractory prostate
cancer in the United States. In this study, we aimed to investigate the results of this
treatment modality in metastatic prostate cancer patients from Iran.
Methods:We evaluated PSA response and bone pain relief in 18 metastatic prostate
cancer patients who underwent treatment with docetaxel at a dose of 75 mg/m2
intravenously on the first day of treatment. The treatment was repeated every three weeks
(6 cycles) along with 10 mg of prednisolone.
Results: Of 18 patients, 39% had > 50% decline in PSA levels.There were 16% of
the patients with a PSA decline of approximately 30% to 50% of the pre-treatment levels.
In addition, 29% of the patients had progressive PSA levels during chemotherapy. Among
them, 55% had significant pain relief.
Conclusion: This research showed the effectiveness of docetaxel to decrease PSA
levels in metastatic hormone-refractory prostate cancer patients from Iran. Docetaxel
was also valuable in alleviation of pain in these patients. However, prospective studies
should validate this approach.
